ATAD1 and malaria: The availability of transgenic P. berghei that expresses P. falciparum MSP1-19 and GFP protein provides a murine model to evaluate protective efficacy in vivo of anti-MSP1-19 antibodies, including those elicited by the PfCP-2.9 malaria vaccine in human volunteers.